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Purpose. P-glycoprotein (P-gp), a membrane ATPase expelling many structurally unrelated compounds
out of cells, is one of the major contributors to multidrug resistance. It is enriched in cold TritonX-100
insoluble membrane domains (i.e., rafts). The purpose of this work was to characterize the ATPase
activities of raft preparations from P388 cells overexpressing P-gp (P388/ADR) or devoid of P-gp (P388)
and to establish a P-gp–enriched screening system for P-gp–interfering compounds.
Methods. Rafts were extracted with cold TritonX-100. The ATPase activity was characterized in 96-well
plates using a fluorescence assay.
Results. The ATPase activity per mg protein was about five times higher in P388/ADR rafts than in
crude membranes. The anti–P-gp antibody C219 inhibited 20% of the activity in P388/ADR rafts but
only about 10% of the activity in P388/ADR crude membranes and had no effect on the activity of P388
rafts. The known P-gp–activating compounds verapamil, progesterone, and valinomycin revealed the
typical bell-shaped activity/concentration profiles in P388/ADR rafts, indicative for activation at low
compound concentrations and inhibition at concentrations >10 to 100 M. The inhibitory effect was also
observed in P388 rafts.
Conclusions. Extracted rafts are rich in functional ATPases. Rafts from P-gp–overexpressing cells
display P-gp–typical ATPase activity and provide an easy, P-gp–enriched screening system.
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INTRODUCTION
P-glycoprotein (P-gp) is the most extensively studied ef-
flux protein involved in multidrug resistance. It is classified as
an ATPase belonging to the ABC (ATP-binding cassette)
superfamily of membrane transporters. It is characterized by
12 putative membrane-spanning domains, two Walker re-
gions corresponding to the two ATP binding sites, and post-
translational modifications comprising phosphorylation and
glycosylation. P-gp has been described to reduce the intracel-
lular level of a large number of structurally unrelated lipo-
philic compounds including numerous cell toxic agents. Un-
der physiologic conditions, it is mainly expressed in barrier
cells such as epithelial cells of the gastrointestinal tract or
endothelial cells of the brain and testes (1). However, P-gp
expression is upregulated in different types of tumor cells
upon treatment with chemotherapeutic agents, which often
results in a generalized chemotherapy resistance of the tumors.
As has been shown, P-gp has a basal ATPase activity in
absence of xenobiotics (1), indicating that P-gp has a physi-
ologic function beyond the removal of toxic entities. In the
presence of exogenous substrates, modulators, and inhibitors,
the ATPase activity is changed. It is assumed that P-gp rec-
ognizes substrates and modulators within the cytosolic leaflet
of the plasma membrane (1) or in the cytosol (2). Substrates
are transported either to the outer membrane leaflet or to the
extracellular space. Modulators, also named reversing agents
or chemosensitizers, inhibit the P-gp–driven substrate efflux
out of the cell. There is evidence that modulators compete
with the substrates for the binding sites and, although being
translocated by the protein as indicated by a stimulation of
the ATPase activity, their net flux remains unchanged due to
a simultaneously occurring, P-gp–independent fast perme-
ation of the compound (3).
There have been many attempts to unravel the structural
patterns that are recognized by this so-called efflux pump
(4–9). However, no clear structural characteristics to be
screened for in drug libraries have emerged so far to identify
substrates or modulators with a low failure rate. Considering
the current trend to look for rather unspecific structure simi-
larities (6) and seen the huge number of P-gp–interfering
agents, the bottleneck lies clearly in the availability of suffi-
ciently large data bases of experimentally confirmed sub-
strates and modulators.
Biologic assays for the identification of P-gp–interfering
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compounds are therefore needed in drug development and to
generate data bases to feed the in silico approach (10,11).
Different types of assays are currently used to identify and
characterize compounds that interact with P-gp. Transport
studies across tight monolayers of P-gp–overexpressing cells
and efflux or influx studies with such multidrug-resistant cells
allow to identify P-gp substrates, modulators, or inhibitors. In
a different approach, fluorescent probes have been used as
indicators of conformational changes of P-gp upon binding of
substrates, modulators, or inhibitors (12), and Landwojtowicz
et al. (13) developed a screening method for P-gp interaction
based on the translocation-induced pH-change in the extra-
cellular microenvironment of cultured cells. A straightfor-
ward option to identify P-gp–interfering compounds is to di-
rectly measure the ATPase activity of P-gp allowing relatively
high throughput of compounds. The analytics in ATPase as-
says are independent of the tested compounds while for trans-
port assays the compounds have to be individually quantified
(10,14). ATPase assays identify substrates, modulators, and
inhibitors in one run, though without distinguishing between
them. In transport assays, substrates and modulators or in-
hibitors, respectively, have to be screened in separate assays,
the latter two in presence of a known substrate. ATPase as-
says can be performed with material that can be prepared in
advance and be stored and shipped, whereas transport assays
generally require living cells in the assay. ATPase assays have
been developed with different membrane fractions such as
enriched plasma membranes (15), crude membranes (11), and
enriched microsomal membranes (16). In addition, the
ATPase activity of purified P-gp was studied after reconsti-
tution of P-gp into proteoliposomes (17,18).
P-gp has been found to be located in detergent-insoluble,
glycosphingolipid and cholesterol rich membrane domains,
the so called rafts (19–23), together with several other mem-
brane proteins that are involved in cell signaling (24). It re-
mains open whether these proteins display their intrinsic ac-
tivity in isolated rafts. If so, these preparations could be used
to specifically study protein functions on isolated membrane
domains. In this work, we show that cold 1% TritonX-100
insoluble membrane domains from P-gp–overexpressing
P388/ADR cells prepared by the method of Brown and Rose
(25) display P-gp–specific ATPase activity which is responsive
to known P-gp substrates, modulators, and inhibitors. With
this well-defined source of P-gp, we established an ATPase
assay to screen for compounds interfering with P-gp.
MATERIALS AND METHODS
Chemicals
Adenosine triphosphate, di-Na+ (ATP) #A2383, adeno-
sine diphosphate, di-Na+ (ADP) #A2754, cyclosporin A
#30024, indomethacin #I7378, orthovanadate, Na+ #S6508,
progesterone #P0130, (±)-propranolol #P0884, valinomycin
#V0627, and (±)-verapamil #V4629 were purchased from
Sigma (Buchs, Switzerland). Bovine serum albumin (BSA)
#05480, dithiothreitol (DTT) #43815, NADH #43420, ouabain
#75640, phosphoenolpyruvate #79418, and pyruvate kinase
#83330 were from Fluka (Buchs, Switzerland) and 3H-
TritonX-100 #ART892 from ARC (American Radiolabeled
Chemicals, St. Louis, MO, USA). Lactate dehydrogenase
#127876 and the protease inhibitor cocktail Complete were
supplied by Roche Diagnostics (Basel, Switzerland). All other
chemicals were of analytical grade.
Cell Cultures and Antibodies
P388 cells were purchased from the Japan Health Science
Research Resources Bank (Osaka, Japan) and P388/ADR
cells from the National Cancer Institute (Frederick, MD,
USA). Cells were grown in suspension in RPMI1640 medium
(Invitrogen Corp., Basel, Switzerland) containing 10% heat-
inactivated fetal bovine serum and split 1:10 every 3 to
4 days. The monoclonal mouse antihuman P-gp antibody
C219, antihuman CD44 antibody and antihuman placental
alkaline phosphatase antibody were supplied by DAKO Corp
(DakaCytomation, Carpinteria, CA, USA).
Preparation of Rafts
Rafts were prepared as described by Brown and Rose
(25) with slight modifications. About 109 cells (150 to 200 mg
protein) were incubated for 20 min with 2 ml TNE/TX-100
buffer [25 mM Tris, 150 mM NaCl, 5 mM EDTA, and Com-
plete, pH 7.4 (TNE), containing 1% (v/v) TritonX-100] on ice
and homogenized with 50 strokes at 1000 rpm using a Dounce
homogenizer. The homogenate was transferred to an equal
volume of 80% (w/v) sucrose in TNE into a centrifuge tube
and overlaid with 2 ml each of 30%, 20%, 10% and 1.5 ml of
5% sucrose in TNE. After centrifugation at 200,000 × g for 19
h at 4°C in a SW41Ti rotor (Beckman Instruments, Fullerton,
CA, USA), rafts were visible as a turbid band in the upper
part of the centrifuge tube corresponding to a density range
between 1.04 and 1.09 g/cm3 as determined from the refrac-
tive indices (refractometer from Bellingham and Stanley,
Turnbridge Wells, UK). Fractions of 1 ml were collected from
the top of the tube (fractions 1 to 11). Quantification of total
protein was performed with the DC protein assay kit from
Bio-Rad (Hercules, CA, USA), which is based on the method
of Lowry (26) using BSA as standard. The pooled raft frac-
tions 4 to 6 contained about 0.3 mg protein. Aliquots were
stored at −20°C.
Thin layer chromatography analysis of the lipids revealed
that the raft fraction was enriched in cholesterol (un-
esterified) as compared to the total cell lysate and the cold
TritonX-100 soluble fraction. Rafts contained about 37%
(mol/mol of total lipids) cholesterol while cholesterol ac-
counted for about 30% in the total cell extracts and for about
23% in the soluble fraction (data not shown).
The hydrodynamic mean diameter of the isolated rafts
was analyzed using a Malvern Zetasizer 3000 HSA. Raft frac-
tions typically showed average mean diameters between 240
and 280 nm with polydispersity indices between 0.4 and 0.5,
indicating a broad size distribution. No aggregates or precipi-
tates were detectable from the correlogram.
The pooled raft fractions contained 6.5 M residual Tri-
tonX-100, as estimated from a preparation with 2 MBq 3H-
TritonX-100. Additional TritonX-100 up to a total concentra-
tion of 16.5 M had no influence on the basal ATPase activity
of P388/ADR rafts. At a concentration of about 100 M Tri-
tonX-100 the activity was reduced to about 50%.
Preparation of Crude Membranes
Crude membranes of P388 and P388/ADR cells were
prepared according to (11) using ATPase buffer (50 mM Tris,
6 mM MgCl2, 0.5 mM EDTA, pH 7.4) containing Complete
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and 1 mM DTT. The crude membrane fraction prepared from
4 × 108 cells (60 to 80 mg protein) contained about 0.8 mg
protein. Aliquots were stored at −20°C before the ATPase
assays.
SDS-PAGE and Immunoblotting
Protein patterns and P-gp contents were analyzed by so-
dium laurylsulfate-polyacrylamide gel electrophoresis [SDS-
PAGE (7.5% SDS)] with subsequent silver staining (Bio-
Rad) or immunoblotting with the anti–P-gp antibody C219
(14). For SDS-PAGE, the fractions of the density gradient
were diluted to 3 ml with TNE and centrifuged at 250,000 × g
for 3.5 h at 4°C to pellet the soluble proteins and the rafts,
respectively. The pellets were resuspended in 100 l electro-
phoresis buffer and analyzed as described above.
Kinetic Assay
ATPase activities were determined in 96 well plates
(Corning, flat bottom, black, #3915, Corning, Acton, MA,
USA) with a total sample volume of 200 l per well using a
modified protocol of Ref. (27). Between 6 and 12 l of the
pooled raft fractions from the density gradient, containing 1
g protein, or crude membranes corresponding to 5 g pro-
tein, respectively, were mixed with ATPase buffer containing
0.5 mM phosphoenolpyruvate (a stock solution was first ad-
justed to pH 7.4 with NaOH), 225 M NADH, 30 U/ml py-
ruvate kinase, 44 U/ml lactate dehydrogenase, 1 mM DTT,
and the compound to be tested. The pH of the mixture was
checked and the plate was shaken and incubated at 37°C for
15 min before the start of the experiment. At time zero, 30 l
of 60 mM ATP in ATPase buffer adjusted to pH 7.4 with
NaOH were added to the wells using the injector of the plate
reader (Synergy HT Bio-Tec, Winooski, VT, USA). Fluores-
cence was measured every 75 s for 2 h (excitation and emis-
sion at 340 and 460 nm, respectively). At the end of the ex-
periment, the pH was checked again to exclude any effects by
pH changes on the activity measurements. The NADH con-
centrations were calculated from the fluorescence using an
NADH calibration curve and ATPase activities were calcu-
lated from the linear range of the NADH concentration/time
profiles, typically between 20 and 120 min. Oxidation of 1 mol
NADH corresponds to the hydrolysis of 1 mol ATP. Values
corresponding to the NADH decrease in control samples
without rafts were subtracted from the measured ATPase ac-
tivities (typically about 10%). The assay was optimized for
our experimental conditions regarding pH stability and excess
of ADP recycling enzymes, substrates and cofactors.
DTT, Complete, and sucrose in the concentrations used
had no effect on the basal ATPase activity. For all compounds
tested in the ATPase assay no influence on the size distribu-
tion of the rafts was observed for the concentration range
used. As tested with ADP as a substrate, verapamil had no
effect on the activity of the ADP recycling enzymes at all
tested concentrations.
Data Analysis
The kinetics of the ATPase as a function of the ATP
concentration were analyzed with the Michaelis-Menten
equation with KM as the Michaelis-Menten constant and Vmax
as the maximal activity (28):
v =
VmaxATP
KM + ATP
(1)
The apparent activities Vapp in the presence of effectors (ac-
tivators or inhibitors) were fitted from the Vapp/concentration
profiles (28).
For all activators, the profiles of Vapp vs the logarithm of
the concentrations were bell-shaped, indicative for activation
at low concentrations and inhibition of activity or loss of ac-
tivation at higher concentrations. Data were fitted as follows:
Vapp = Vbasal +
Vx
K + x +
x2
Ki
(2)
V denotes the difference between the activity at an effector
concentration x →  if no loss of activating effect or inhibition
occurred, and the basal activity Vbasal without effector. K is
the apparent dissociation constant of the enzyme/effector
complex. Ki describes the apparent dissociation constant of
the inhibiting activator molecule from the enzyme/activator
complex.
A decrease in activity was consistently observed at acti-
vator concentrations >100 M (propranolol >130 M). For
the determination of the activator parameters Vapp and K,
alternatively, activator concentrations >100 M (>130 M for
propranolol) were ignored for the fitting and Eq. (3) was used
instead of Eq. (2):
Vapp = Vbasal +
V
1 +
K
x
(3)
The same equation was also used for the true inhibitors
tested. It can alternatively be written as Eq. (4) (28):
Vapp = Vbasal + V −
V
1 +
x
K
(4)
and reveals negative values for V’ corresponding to the in-
hibitory effect (i.e., the difference between the basal activity
and the residual activity at x → ).
For clarity, most fits are shown in plots with a logarithmic
concentration scale. Data were fitted using the Excel Solver
tool. The 95% confidence intervals of the fits were calculated
according to Ref. (29).
RESULTS
Isolation and Characterization of Rafts from P388/ADR
and P388 Cells
Rafts from P388/ADR and P388 cells were prepared as
described in “Materials and Methods.” After the density gra-
dient centrifugation of the cold TritonX-100 treated cells, the
density fractions containing protein (fractions 4 to 11) were
analyzed by SDS-PAGE and immunoblotting. Blotting with
the monoclonal P-gp antibody C219 revealed enhanced levels
of P-gp in the raft fractions (fractions 4 to 6) as compared to
the fractions with higher densities containing the TritonX-100
soluble proteins (Fig. 1A). Analysis of the total cell lysate and
rafts prepared from P-gp–devoid P388 cells (the latter not
shown) revealed similar protein patterns but no detectable
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amounts of P-gp on the immunoblot (Fig. 1 B and C). The
comparison of the immunoblots of a representative P388/
ADR raft preparation with the crude membrane preparation
of the same cell type (Fig. 1D) shows that rafts contain about
12 times more P-gp per mg protein than crude membranes.
Kinetics of the ATPase Activity in P388/ADR Rafts
The total ATPase activity of the raft preparations of
P388/ADR cells was determined at different ATP concentra-
tions up to 14 mM. Activities followed a Michaelis-Menten
function up to about 10 mM ATP (Fig. 2). At higher concen-
trations, the Michaelis-Menten conditions were not main-
tained. The fitted apparent KM value [see “Materials and
Methods,” Eq. (1)] for the ATP concentration range between
0 and 10 mM was 2.0 mM. As a consequence, the ATP con-
centration for all assays was fixed at 9 mM. This concentration
is far above the published KM values for P-gp, that is, 0.3 to
1.1 mM (30).
Differentiation Between P-gp–related and Other
ATPase Activities
Similar basal ATPase activities were determined in raft
preparations from P388/ADR (1.53 ± 0.33 × 10−4 mmol min−1
per mg total protein; n  33) and P388 cells (1.34 ± 0.28 ×
10−4 mmol min−1 per mg total protein; n  21). ATPase
activities in the same range were also found for rafts of
MDCK cells (Madin Darby Canine Kidney cells, a cell line
with an epithelial phenotype growing to confluent monolay-
ers) and for rafts of the P-gp–transfected MDCK cells, that is,
mdr1-MDCK cells (data not shown). For crude membranes of
P388/ADR cells, the basal activity was about 5 times lower
than in P388/ADR rafts, that is, 3.2 ± 0.9 × 10−5 mmol min−1
per mg total protein; n  3.
To characterize further the ATPase activity of the raft
preparations of P388/ADR and P388 cells, the influence of
known ATPase inhibitors was investigated. Results originat-
ing from data fitting with Eq. (3) are expressed as residual
activities (i.e., % of the basal activity). Confidence intervals of
the fitted activities at  0.05 are shown in brackets. The mouse
monoclonal P-gp antibody C219, which was described to re-
duce the ATPase activity of a plasma membrane enriched
fraction of a P-gp positive tumor cell line (15), decreased the
activity of P388/ADR rafts to 79.8 ± 2.2% between 0.67 and
2.50 g antibody per ml and 5 g raft proteins per ml. The
fitted residual relative activity at infinite antibody concentra-
tion is 72.2% (4.4%). C219 had no significant influence on the
ATPase activity of P388 rafts (∼98% (3.6%)) (Fig. 3A). With
crude membranes (25 g/ml) prepared from P388/ADR cells,
the C219 antibody reduced the ATPase activity to 90.0 ±
1.2% between 1 and 7.5 g antibody per ml. Placental alka-
line phosphatase antibody and CD44 antibody were used as
negative controls. Both of them had no inhibitory effect on
the ATPase activity of P388/ADR rafts (data not shown).
Figure 3B shows the influence of orthovanadate, a known
inhibitor of various types of ATPases (31,32), on P388/ADR
and P388 rafts. In both cases, the activity was similarly re-
duced in a concentration-dependent manner. At 0.05 M or-
thovanadate, about 10% inhibition was observed and highest
inhibition was obtained at concentrations >5 M. The re-
sidual activity calculated from the fit value was 31.1% (3.2%)
for the P388/ADR rafts and 48.4% (4.7%) for the P388 rafts.
Ouabain, an inhibitor of the Na+/K+-ATPase, was tested in
concentrations up to 400 M. A reduction in ATPase activity
to 88.9 (3.8%) and to 93.7% (6.0%), respectively, was found
in the raft preparations of P388/ADR and P388 cells (Fig.
3C). This indicates that about 90% of the observed activity
originates from other ATPases than the Na+/K+-ATPase. Cy-
closporin A is frequently used as a P-gp inhibitor for in vivo
and in vitro experiments. We found a concentration-
dependent inhibition of the ATPase activity in both P388/
ADR and P388 rafts (Fig. 3D). At 0.2 M, the reduction was
between 5% and 6% in both types of rafts. The residual ac-
tivity as determined from the fit value was 60.0% (4.7%) for
P388/ADR rafts and 70.6% (8.1%) for P388 rafts.
Fig. 1. P-gp enrichment in P388/ADR rafts. (A) The protein-
containing fractions of the density gradient of cold TritonX-100
treated P388/ADR cells were analyzed by Western blotting with the
monoclonal P-gp antibody C219. Of each fraction, 5 g protein were
loaded on the gel. Fractions 4 to 6 correspond to the raft fractions.
(B) Silver stain and (C) Western blot of the total cell lysates of P388
and P388/ADR cells (5 g protein each). (D) Western blot and im-
muno staining with C219 of rafts (a) and crude membranes (b) pre-
pared from P388/ADR cells. (a) 2.5 g protein, (b) 25 g protein. The
ratio of the integrated optical densities of the two bands is about 1.2
as estimated using the software Scion Image (Scion Corporation).
Fig. 2. ATPase activity of P388/ADR rafts. ATPase activities of
P388/ADR rafts were determined at different ATP concentrations at
37°C, pH 7.0. A representative experiment is illustrated with mean
values and standard deviations from three wells each. The line shows
the fitted Michaelis-Menten function with KM 2.0 mM and Vmax 2.0 ×
10−4 mmol min−1 per mg protein.
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Influence of Verapamil on the ATPase Activity
Verapamil is one of the best studied P-gp modulators
(33). It activates the P-gp ATPase activity at low concentra-
tions but has an inhibitory effect at higher concentrations
(11). To start out, we investigated the influence of verapamil
on the ATPase activity of P388/ADR and P388 rafts as well as
of crude membranes of P388/ADR cells (Fig. 4 A and B).
Fig. 3. Influence of ATPase inhibitors on the ATPase activity of
rafts. Rafts isolated from P388/ADR cells () and from P388 cells ()
were incubated with different concentrations of P-gp antibody C219
(A), orthovanadate (B), ouabain (C), and cyclosporine A (D), re-
spectively, and ATPase activities were determined as described in the
text. Data represent mean values and standard deviations from three
independent experiments each. The solid lines indicate the fitted
functions using Eq. (3) with the 95% confidence intervals (dotted
lines). Fit parameters are shown in the panels.
Fig. 4. Influence of verapamil on the ATPase activity of rafts and
crude membranes. (A and B) ATPase activities of P388/ADR rafts
(), P388 rafts (), and P388/ADR crude membranes () were de-
termined at different verapamil concentrations. Data represent mean
values and standard deviations from 3 independent experiments
(rafts) or 3 wells each (crude membranes) in a linear plot (A) and a
plot with a logarithmic scale for concentrations (B). The solid lines
indicate the fitted functions using Eq. (2) (a; highest concentration
excluded from the fit, see “Materials and Methods”) and Eq. (3) (b;
two highest concentrations excluded) with their 95% confidence in-
tervals (dotted lines). The fit parameters are shown in panel B. Ex-
clusion of the three highest concentrations and fit with Eq. (2) results
in V/Vbasal 0.40 and K 2.86 M. (C) Influence of verapamil at dif-
ferent concentrations on the ATPase activity of P388/ADR rafts in
presence of 2.7 g antibody C219 per ml () and without antibody
(). Data represent mean values and standard deviations from six
independent experiments each.
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Verapamil enhanced the ATPase activity of the P388/ADR
rafts at concentrations up to about 100 M and of crude
membranes up to about 10 M but had no activating effect on
the raft preparations from P388 cells. At higher verapamil
concentrations, the ATPase activity was reduced in all three
preparations. These results indicate that verapamil at lower
concentrations has a specific activating effect on P-gp,
whereas at higher concentrations a nonspecific inhibitory ef-
fect on ATPases is observed, independently of the presence
of P-gp. Similar activity/concentration profiles were found for
rafts from mdr1-MDCK and MDCK cells. The profile was
bell-shaped in the case of the mdr1-MDCK rafts but no in-
crease in activity was observed with the MDCK rafts (data
not shown).
To corroborate further that the verapamil-induced in-
crease in ATPase activity was related to P-gp, ATPase activi-
ties of P388/ADR rafts were determined at different vera-
pamil concentrations in the presence of 2.7 g/ml antibody
C219. As shown in Fig. 4C, the antibody significantly reduced
the activating effect of verapamil on the ATPase activity of
these rafts.
The verapamil concentration-dependent activities of
P388/ADR rafts were further analyzed by curve fitting con-
sidering verapamil as an activator of the ATPase activity with
loss of activation at higher concentrations (Eq. 2). The highest
concentration (400 M) was excluded from the fit, being be-
low the basal activity. The fitted bell-shaped curve and the fit
parameters V/Vbasal and KM are shown in Fig. 4. The fitted
parameter Ki is of minor interest, as the reduction in activity
has been demonstrated to be an additive effect resulting from
the inhibition of several ATPases.
To exclude the influence of unspecific effects on the fit
parameters, an independent fit of the same activity/
concentration profile was made using the activator function
(Eq. 3) excluding verapamil concentrations >100 M. The fit
curve and parameters are indicated in Fig. 4. Excluding con-
centrations >13 M resulted in similar parameters (see legend
to Fig. 4). Equation 2 (activation and loss of activation) re-
vealed V/Vbasal and KM values that were within a factor of 1.5
and 2, respectively, of the parameters resulting from Eq. (3)
(activation only).
Influence of Known P-gp Activators and an MRP Activator
on the ATPase Activity
Beside verapamil the known P-gp ATPase activators
progesterone (11), propranolol (7), and valinomycin (11) as
well as indomethacin, which activates the ATPase activity of
the multidrug resistance–associated proteins MRP1 and
MRP2 in the studied concentration range (34), were tested in
the ATPase assay with rafts. The activity/concentration pro-
files are shown in Fig. 5A–5D. With the known P-gp activa-
tors, the typical bell-shaped curves were obtained with P388/
ADR raft preparations, whereas no activating effect on the
ATPases of the P388 rafts was observed. Similarly to vera-
pamil, at higher concentrations progesterone and propranolol
reduced the activity also in rafts from P388 cells (valinomycin
was not investigated). As elaborated with verapamil, fit data
plotted in Fig. 5 are based on the activator function (Eq. 3).
The corresponding fit values for V/Vbasal and K are indi-
cated. Indomethacin had no activating effect on the ATPase
activity of P388/ADR rafts (Fig. 5D). However, as the other
tested compounds, it inhibited the ATPase activity at high
concentrations (i.e., above 14 M).
Fig. 5. Influence of (A) progesterone, (B) propranolol, (C) valino-
mycin, and (D) indomethacin on the ATPase activity of rafts. The
ATPase activities at different concentrations of the tested compounds
were determined in P388/ADR rafts () and P388 rafts (; as
indicated). Data represent mean values and standard deviations of
three independent experiments each with the fitted functions using
Eq. (2) (solid lines; two highest concentrations excluded from the fit,
see “Materials and Methods”) and their 95% confidence intervals
(dotted lines). The fit parameters V/Vbasal and K are shown in the
panels.
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DISCUSSION
Using the cold TritonX-100 extraction method combined
with a sensitive ATPase assay, we can show here for the first
time that P-gp and other ATPases are functional in isolated
rafts of P-gp–overexpressing cells, which expel typical P-gp
substrates (35). The raft preparations can be used as straight-
forward system for the screening of drug-related effects on
raft-associated ATPases.
The total basal ATPase activity in our assay with rafts
from P388/ADR and P388 cells was between 1 and 2 × 10−4
mmol min−1 per mg protein. This is similar to the published
basal ATPase activities of various cell membrane fractions of
different types of multidrug-resistant cells, namely the plasma
membrane fraction of P-gp–overexpressing CHRB30 cells
(36), the microsomal membrane fraction of the tumor cell line
CR1R12 (37), and crude membrane vesicles form actinomy-
cin D-resistant chinese hamster lung fibroblasts DC-3F/ADX
(11), all revealing activities between 1 and 4 × 10−4 mmol
min−1 per mg total protein. Reconstitution of purified P-gp
into proteoliposomes containing the lipid extract of Esche-
richia coli led to a basal ATPase activity of 3 × 10−2 mmol
min−1 per mg protein (38) and in a mix of E. coli phospho-
lipids, phosphatidylcholine, phosphatidylserine, and choles-
terol to 1.75 × 10−4 mmol min−1 per mg protein (39).
From the partial inhibition of the ATPase activity of
P388/ADR rafts by the monoclonal P-gp antibody C219, we
conclude that 20% to 30% of the basal activity of P388/ADR
rafts (in absence of K+ and Ca2+) is contributed by P-gp. The
antibody C219 has been discussed as a specific inhibitor of the
P-gp ATPase by blocking the binding of ATP to its binding
sites on the protein (15,40). The antibody-inhibited activity of
P388/ADR rafts corresponds to 2 to 6 × 10−5 mmol min−1 per
mg protein. In the plasma membrane enriched fraction of
adriamycin-resistant human breast adenocarcinoma cells
MCF7/ADR, C219 reduced the ATPase activity by 50% in
presence of Na+/K+- and Ca2+-ATPase blockers (15), result-
ing in a similar P-gp activity of 3.6 × 10−5 mmol min−1 per mg
protein. It remains open how the patterns of ATPases differ
between rafts, crude membranes, and plasma membrane en-
riched fractions. It can be assumed that rafts contain a sub-
fraction of the plasma membrane–located ATPases, as shown
here for P-gp. The existence of raft- and nonraft-localized
ATPases has been shown for yeast (41). The preparation pro-
cedures and ATPase activities of the three systems are sum-
marized in Table I. The preparation of rafts involves less steps
than the preparations of the other two systems and the re-
sulting P-gp activity per mg protein is significantly higher in
rafts than in crude membranes from the same cells.
Considering the 5 times higher ATPase activity per mg
protein in P388/ADR rafts compared to crude membranes
and the fraction of this activity that is inhibited by the P-gp
antibody C219 (i.e., 20% in rafts and 10% in crude mem-
branes, respectively), the ratio between the P-gp ATPase ac-
tivities per mg protein of the two systems is estimated to be
10. This is in agreement with the about 12 times higher ratio
of P-gp to total protein in rafts as compared to crude mem-
branes, indicating that the basal ATPase activity of a P-gp
molecule is similar in the two systems.
To get an estimate on the contribution of other types of
ATPases than P-gp on the total ATPase activity of P388/
ADR and P388 rafts, different ATPase inhibitors were tested.
More than 50% of the basal ATPase activity in both raft types
was inhibited by >5 M orthovanadate, an inhibitor of several
Table I. Comparison of the Preparations and ATPase Activities of Rafts and Crude Membranes from P388/ADR Cells and of the Plasma
Membrane–Enriched Fraction from MCF7/ADR Cells
Rafts of P388/ADR cells
Crude membranes of P388/ADR
cells
Plasma membrane–enriched
fractions of MCF7/ADR cells
[Ref. (15)]
Preparation steps Cultured cells Cultured cells Cultured cells
20 min incubation with TritonX-100 Suspension in ATPase buffer Suspension in homogenization
buffer
Homogenization Homogenization Homogenization
Short centrifugation to remove
nuclei and debris
Short centrifugation to remove
nuclei and debris
19 h centrifugation on a sucrose
gradient
100 min centrifugation on a
sucrose cushion
18 h centrifugation on a
sucrose gradient
Collection of the band Collection of the band Collection of the band
3 times 15 min washing (soluble
proteins)
20 times passage through a
22-gauge needle
30 min incubation in water to
disrupt vesicles
Protein yield per 109 cells 0.3 mg 2 mg
Mean basal ATPase activity
per mg proteina
1.53 × 10−4 mmol min−1 (0.33 × 10−4
mmol min−1; n  33)
3.2 × 10−5 mmol min−1 (0.9 × 10−5
mmol min−1; n  3)
Basal ATPase activity per
mg protein assigned to P-gpb
3.2 × 10−5 mmol min−1 (20% of total
basal activity)
3.2 × 10−6 mmol min−1 (10% of
total basal activity)
3.6 × 10−5 mmol min−1
ATPasesc Raft-located ATPases Membrane ATPases (rafts and
non-rafts)
Membrane ATPases, enriched
in plasma membrane
ATPases (rafts and nonrafts)
a Standard deviations and number of independent experiments (n) in brackets.
b As estimated from the antibody C219-inhibited fraction of the ATPase activity.
c ATPases that are expected in the respective fractions.
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types of ATPases (31,32) including P-gp (42). In microsomal
membrane vesicles, the ATPase activity was reduced to about
12% by orthovanadate (37). Cyclosporin A is frequently used
as P-gp inhibitor but inhibits also other ATPases such as Na+/
K+-ATPases (43) and Ca2+-pumps (44,45). One hundred M
cyclosporin A reduced the basal ATPase activity of P388/
ADR and P388 rafts to about 60% and 70%, respectively.
This is in a similar range as shown for crude membranes (11).
Only about 10% of the ATPase activity in P388/ADR and
P388 rafts were inhibited by ouabain and therefore assigned
to the Na+/K+-ATPase. From this we conclude that the
ATPase activities determined with the raft preparations un-
der our experimental conditions result from the activities of
different types of ATPases.
The bell-shaped ATPase activity/concentration profiles
are typical for the P-gp activators. The maximal activating
effect of verapamil on the ATPase activity of P388/ADR rafts
was observed at 10 to 40 M, of progesterone around 40 M,
of propranolol around 130 M and of valinomycin around 40
M. This is in the same range as described for egg phospha-
tidylcholine proteoliposomes which displayed maximal
ATPase activity at 10 M verapamil (46) and for crude mem-
brane vesicles where maximal ATPase activation was found
at 30 M verapamil and 60 M progesterone (47). The
ATPase activating effect of verapamil was significantly re-
duced by the P-gp antibody C219, indicating that the ob-
served activity-changes are associated with P-gp. To conclude,
rafts from P-gp overexpressing cells show typical P-gp
ATPase activity and provide therefore an ideal system to
study the influence of coumpounds on the ATPase activity of
the multidrug-resistance protein.
In our assay with P-gp–devoid rafts (i.e., rafts from P388
cells), concentrations of >130 M verapamil, >14 M proges-
terone, and >14 M propranolol significantly reduced the
ATPase activity in the absence of P-gp. The observed inhibi-
tory effect on the ATPase activity in P388/ADR rafts at high
activator concentrations is thus not P-gp specific but is at least
in part the result of the inhibition of one or more other
ATPases. This puts some question marks on the quantitative
evaluation of the effects at inhibitory activator concentra-
tions. In consideration of the relatively high concentrations,
unspecific effects on the biologic system have to be expected.
The fit parameters for verapamil were in the same range
if either activation and inhibition or only activation at the
lower concentrations were taken into account (Eq. 2 and Eq.
3, respectively). Good estimates of the activating effect (V/
Vbasal) and of the concentration mediating half maximal effect
(KM) could be made. These parameters are helpful for the
comparison of different compounds and to estimate their ef-
fect on P-gp under therapeutic conditions. In our study vera-
pamil had the lowest KM of the tested activators (i.e., it was
effective at the lowest concentration). KM was between 2.4
M (fit with Eq. 3) and 4.8 M (fit with Eq. 2), which both are
above the therapeutic plasma concentration range of 0.2 to
1.5 M (48). Progesterone activated P-gp most, reaching 1.5
times the basal activity at 40 M. The fitted parameters V’/
Vbasal and KM were 0.67 and 8.9 M, respectively. Therapeu-
tic and endogenous plasma levels are far below the fitted KM,
reaching about 50 nM (500 nM in pregnancy).
The existence and appearance of rafts in cell membranes
is a matter of interesting debates (49). For our assay, it is not
of primary interest whether the extracted rafts are native do-
mains of the cell membranes or whether they assemble in 1%
cold TritonX-100. Extracted rafts of multidrug-resistant cells
provide a simple, P-gp–enriched test system and show the
characteristic P-gp ATPase activity. They are easily extract-
able from whole cells. The results with different raft prepa-
rations were reproducible, and the assay measuring NADH
oxidation using a fluorescence plate reader is relatively sen-
sitive. One preparation of rafts from 109 cells (150 to 200 mg
protein) provides enough material for about 300 kinetic mea-
surements (i.e., three 96-well plates).
CONCLUSIONS
To conclude, we show here for the first time that cold
TritonX-100 insoluble membrane domains of P-gp–
overexpressing cells contain different types of active
ATPases, display typical P-gp–related ATPase activity, and
can be used as an easy screening system for P-gp–interfering
compounds.
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